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GM-CSF drives dysregulated hematopoietic stem
cell activity and pathogenic extramedullary
myelopoiesis in experimental spondyloarthritis
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Nicole J. Horwood 1,3, Stephen N. Sansom 1 & Thibault Griseri 1*
Dysregulated hematopoiesis occurs in several chronic inflammatory diseases, but it remains
unclear how hematopoietic stem cells (HSCs) in the bone marrow (BM) sense peripheral
inflammation and contribute to tissue damage in arthritis. Here, we show the HSC gene
expression program is biased toward myelopoiesis and differentiation skewed toward
granulocyte-monocyte progenitors (GMP) during joint and intestinal inflammation in
experimental spondyloarthritis (SpA). GM-CSF-receptor is increased on HSCs and multi-
potent progenitors, favoring a striking increase in myelopoiesis at the earliest hematopoietic
stages. GMP accumulate in the BM in SpA and, unexpectedly, at extramedullary sites: in the
inflamed joints and spleen. Furthermore, we show that GM-CSF promotes extramedullary
myelopoiesis, tissue-toxic neutrophil accumulation in target organs, and GM-CSF
prophylactic or therapeutic blockade substantially decreases SpA severity. Surprisingly,
besides CD4+ T cells and innate lymphoid cells, mast cells are a source of GM-CSF in this
model, and its pathogenic production is promoted by the alarmin IL-33.
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Long-term hematopoietic stem cells (LT-HSC) differentiatethrough short-term HSC (ST-HSC) and then multipotentprogenitor (MPP) stages into lineage restricted progenitors,
i.e., lymphoid, myeloid, or megakaryocyte/erythroid progenitors1.
Recently, dysregulation of hematopoietic stem and progenitor cell
(HSPC) activity in the bone marrow (BM) has been reported in
several chronic inflammatory diseases, including inflammatory
bowel disease2,3, lupus4, and atherosclerosis5,6. However, the
mechanism by which HSPCs inside the BM detect and respond to
peripheral inflammation affecting remote target tissues remains
elusive. Some clues have emerged from research into anti-
microbial immunity7, where studies have revealed that, although
sheltered inside the BM niche, HSCs are more reactive to envir-
onmental cues than previously appreciated. Indeed, HSCs express
receptors for inflammatory cytokines (e.g., receptors for IFN-α/β,
IFN-γ, and IL-1β) and microbial compounds (e.g., TLR2 and
TLR4), which upon activation trigger HSC proliferation and
differentiation7–9.
In this study, we investigate how HSC and downstream pro-
genitors respond to the systemic inflammation characterizing
spondyloarthritis (SpA). SpA encompasses several inflammatory
arthropathies, including ankylosing spondylitis (AS), psoriatic
arthritis, and enteropathic arthritis, which share common genetic
and environmental triggers and pathophysiological mechanisms10.
These include, for example, involvement of the IL-23/Th17
pathway and intestinal dysbiosis11. SpA is a systemic disease, such
that inflammation affects not only the peripheral and axial joints
but also other tissue sites, especially the barrier surfaces of the skin
and intestine. Mechanistically, inflammation triggered by micro-
bial stress at barrier surfaces together with mechanical stress in the
joints of individuals with a predisposing genetic background are
thought to contribute to SpA development10,12.
At the cellular level, although the immune cell network that
drives SpA is still unclear, genetic and experimental evidence
supports a central role for innate cells in disease development10,12.
For example, in response to microbial or sterile inflammatory
stimuli, macrophages and dendritic cells produce excessive
amounts of cytokines promoting arthritogenic Th17 cell response,
e.g., IL-23, IL-6, and IL-1β. In addition, neutrophils accumulate in
the synovial fluid of SpA patients and inflamed entheses (i.e.,
tendon and ligament insertions into the bone). These over-
activated neutrophils are tissue-toxic owing to release of proteases,
reactive oxygen species, and inflammatory cytokines that con-
tribute to chronic bone and cartilage damage13,14. Importantly,
neutrophils are short-lived cells and their peripheral numbers are
highly dependent on the output from HSPCs in the BM15.
Here, we ask how HSCs and myeloid progenitor cells in the BM
respond to the inflammation targeting peripheral tissues in
arthritis. We utilize a recently described model of SpA character-
ized by chronic arthritis development, enteritis, and systemic
inflammation with numerous clinical features observed in AS
patients16. In particular, we investigate how the chronic inflam-
mation occurring in SpA influences the gene expression programs
of HSCs and MPPs and impacts their differentiation into the
various lineage-committed progenitors. Consequently, we high-
light a key role for granulocyte-macrophage colony stimulating
factor (GM-CSF) in regulating these processes in the BM and at
extramedullary sites. In addition, we identify mast cells (MC) as a
cellular source of GM-CSF during SpA and reveal IL-33 as a potent
inducer of GM-CSF secretion, the latter promoting the production
of tissue-toxic neutrophils in the BM and at extramedullary sites.
Results
Hematopoiesis is biased toward myelopoiesis during SpA.
Given that HSCs express receptors for inflammatory stimuli7, we
hypothesized that HSC activity in the BM may be modulated by
signals that originate remotely in inflamed peripheral organs in
SpA and travel to the BM via the bloodstream. To test this notion,
we utilized arthritis-prone SKG mice17 in the context of a novel
model of SpA in which an IP injection of the microbial poly-
saccharide curdlan, a potent inducer of IL-23-mediated Th17
responses18, triggers a SpA-like phenotype (Fig. 1a) replicating
many features of AS in humans16. We confirmed these obser-
vations as curdlan-injected SKG mice developed a non-resolving
inflammation characterized after ~1 month by severe paw swel-
ling and draining lymph node enlargement, small intestinal
inflammation, and enthesitis associated with ankle swelling and
new bone formation. Conversely, SKG mice injected with
phosphate-buffered saline (PBS) remained healthy (Fig. 1b,
Supplementary Fig. 1a, b). In addition to the joint phenotype, we
observed signs of systemic inflammation in spondyloarthritic
SKG mice, manifesting as pale BM (a sign of anemia), spleno-
megaly (Fig. 1b), an intestinal increase in expression of inflam-
matory genes, i.e., Il1, Il6, Il23, and Tnf (Supplementary Fig. 1c),
and weight loss (Supplementary Fig. 1a).
To identify HSCs and downstream progenitors, we utilized a
well-defined panel of fluorescence-activated cell sorting (FACS)
markers (Supplementary Fig. 1d)19. Compared to healthy controls,
spondyloarthritic mice assessed ~6 weeks after triggering showed a
marked increase in BM of Lineage−Sca1+cKit+ (LSK) cells (Fig. 1c).
Among LSK cells, the percentage of MPPs was considerably
increased in the BM during disease, together with the upstream and
primitive CD34−CD48−CD150+ LT-HSCs (Fig. 1c). Of note,
percentage changes in HSPC were mirrored by similar changes in
absolute cell numbers (Supplementary Fig. 1e) because the total
BM cellularity was unchanged during SpA (Fig. 1d).
We then investigated if the normal balance of differentiation
among hematopoietic lineages was altered by chronic inflamma-
tion. Downstream of HSCs and MPPs, the BM of spondyloar-
thritic mice displayed a ~2.3-fold increase in the percentage and
absolute number of granulocyte–monocyte progenitors (GMP)
compared to healthy mice (Fig. 1e and Supplementary Fig. 1e).
These GMPs are highly proliferative cells that give rise to
neutrophils and monocytes/macrophages20. Bias toward myelo-
poiesis was confirmed functionally by an increase in the number
of colony forming unit-granulocyte macrophage (CFU-GM)
derived from BM in inflamed mice (Fig. 1e). The bias was also
reflected in a decrease in megakaryocyte-erythroid progenitors
(MEP), resulting in an increase in the balance of myeloid to
erythroid progenitors in SpA (GMP:MEP ratio) (Fig. 1e). Greater
myelopoiesis occurred at the expense of erythropoiesis and
lymphopoiesis, with a significant decrease in common lymphoid
progenitors (CLP) during disease (Fig. 1e). These changes in
HSPCs correlated with a significant increase in mature BM
neutrophils during SpA and a decline in BM erythroid and B cells
compared to healthy mice (Fig. 1f). Ultimately, the increased BM
myelopoiesis supported the chronic accumulation of short-lived
neutrophils occurring in the paw joints and small intestine (SI)
during SpA, i.e., ~50 and ~20-fold increases, respectively (Fig. 1g).
These neutrophils had an activated phenotype in SpA, character-
ized by increased FcγRI expression, and production of TNF and
IL-1β (Supplementary Fig. 1f), which are proarthritic cytokines17.
In sum, the non-resolving joint and intestinal inflammation in
spondyloarthritic mice was accompanied in the BM by dysregu-
lated HSPC activity and biased differentiation toward myeloid
progenitors, culminating in an invasion of target organs by
activated and tissue-toxic neutrophils.
HSC and MPP upregulate myelopoiesis associated genes in
SpA. To identify potential modulators of HSPC activity during
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inflammation, we studied the transcriptomes of FACS-sorted
LT-HSCs, ST-HSCs, MPPs, and GMPs from the BM of spondy-
loarthritic and healthy SKG mice. As expected, analysis of RNA-
sequencing data from each of these populations revealed a principal
component of variation that captured the progression from multi-
potency to lineage restriction (PC1, Supplementary Fig. 2a). Closer
inspection of this component revealed that MPPs extracted from
arthritic mice had a transcriptional profile more similar to GMPs
than that displayed by their healthy counterparts. To investigate
this observation, we compared genes significantly differentially
expressed between arthritic and healthy MPPs with those that
showed significant differences between healthy MPPs and GMPs.
We found a strong positive correlation (Spearman’s rho= 0.75,
p= 2.2 × 10−16) between transcriptional changes associated with
SpA development in MPPs and the transcriptional differences
between MPPs and GMPs in healthy SKG animals (Fig. 2a). This
result suggests that MPPs are biased toward expression of pro-
myeloid genes in SpA. For example, we found genes expressed at
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Fig. 1 Hematopoiesis is biased toward myelopoiesis during experimental SpA. a Experimental protocol to induce spondyloarthritis (SpA) in SKG mice.
Single injection of curdlan IP causes non-resolving inflammation of joints, entheses, and small intestine (SI). Samples derived from such “arthritic” SKG
mice culled 4–6 weeks after triggering were compared with PBS-injected “healthy” SKG mice (b–g). b Images of gross pathologic changes observed during
SpA in SKG mice. Front paw: 3D-reconstructed ex vivo µCT radiographs of front paw. Arrow shows new bone formation characteristic of SpA. Scale bars=
1 cm. c Staining of bone marrow (BM) cells with frequencies of progenitors (Sca-1−cKit+) and LSK cells (Sca-1+cKit+) among Lin− cells. Graphs show
frequencies of long-term hematopoietic stem cells (LT-HSC), multi-potent progenitors (MPP), and LSK cells among total cells. d Total count of BM
extracted from one tibia and one femur of each mouse. e BM staining for CD16/32 and CD34, showing frequencies of granulocyte macrophage progenitors
(GMP) and megakaryocyte-erythroid progenitors (MEP) among Lin−cKit+Sca-1− progenitor cells. Graphs show frequencies of GMP and common
lymphoid progenitors (CLP), ratio of GMP:MEP, and number of myeloid CFU-GM colonies obtained from BM cells plated in methylcellulose medium.
f Staining and graphs showing frequencies of mature neutrophils (Ly6G+), B cells (B220+), and erythroid cells (Ter119+ red blood cells) among total BM
cells. g Graphs and staining of cells from paws and small intestine (SI LPL), showing frequency and absolute number of neutrophils (CD11b+Ly6G+). Dots
represent individual mice; horizontal bars indicate mean. Data are representative of three independent experiments (b–g). Groups were compared using
Mann–Whitney U tests. Source data are provided as Source Data file.
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high levels by developing or mature neutrophils, e.g., Elane (elastase
gene) or Ctsg (cathepsin G gene), and more broadly by myeloid
cells, e.g., Lbp, Cd14, and Trem1, to be upregulated in the multi-
potent MPPs in SpA (Fig. 2b and Supplementary Fig. 2b). In fact,
some myeloid genes were already upregulated at the earliest stage
of hematopoiesis, in LT-HSCs, e.g., Lbp, Cd14, and Vldlr (Fig. 2c
and Supplementary Fig. 2b). Furthermore, we noted that Cdk6,
which is essential for the egress of HSCs from quiescence21, and
Plac8 and Cd53, which are involved in enhanced cell cycling22,23,
were upregulated on LT-HSCs in SpA (Fig. 2c), corresponding with
the HSC increase observed in response to arthritis-derived
inflammatory signals. Interestingly, the GM-CSF-receptor coding
gene, Csf2rb, which is a pro-myeloid gene highly expressed by
GMPs and mature myeloid cells24, was upregulated on MPPs and
LT-HSCs in SpA (Fig. 2b, c); this was confirmed at protein level
(Supplementary Fig. 2c). Although the Csf2ra gene coding for the
second subunit of the GM-CSF-receptor was expressed by LT-HSC,
ST-HSC, and MPP, its levels were not increased during disease
(Supplementary Fig. 2d).
As the precise stage at which GM-CSF acts on the
hematopoietic tree (Supplementary Fig. 1d) is unclear and as
we had detected expression of Csf2ra and Csf2rb in GMPs and
also in MPPs and HSCs, we tested their responsiveness to
GM-CSF. The myeloid cell output from GMPs cultured in
pan-myeloid medium was substantially increased in response to
GM-CSF (Supplementary Fig. 2e), and, interestingly, also from
ST-HSCs and MPPs (Supplementary Fig. 2e and Supplementary
Fig. 2f). This early stage responsiveness of HSPCs to GM-CSF was
confirmed in vivo: treatment of curdlan-triggered SKG mice with
GM-CSF for 7 days resulted in LT-HSCs, ST-HSCs, and MPPs
increases (Supplementary Fig. 2g). Furthermore, GM-CSF treat-
ment recapitulated the myeloid-skewed output from HSPCs
observed with SpA, with a BM increase in GMP and neutrophils
but decrease in MEP and mature erythroid cells and B cells
(Supplementary Fig. 2g).
Together, these results revealed that the gene expression program
of HSCs and MPPs is biased toward myeloid cell differentiation
during SpA and that HSPCs are responsive to the pro-myelopoietic
effect of GM-CSF as early as at the HSC and MPP stages, before the
emergence of GMPs and mature myeloid cells.
GM-CSF drives BM myelopoiesis and organ inflammation in
SpA. After showing that HSCs and MPPs are responsive to GM-
CSF, we examined the potential role of GM-CSF on
hematopoietic changes and clinical disease during SpA. CD4
T cells are an important source of GM-CSF2,25. Here, in SpA, we
detected GM-CSF+ CD4 T cells in joint-draining lymph nodes,
but these cells were more abundant in the inflamed joints
themselves (Fig. 3a). In addition, the percentage of GM-CSF
producers among CD4 T cells and their absolute number inside
the paw joints were significantly higher in spondyloarthritic
compared to healthy SKG mice (Fig. 3a). GM-CSF+ CD4 T cells
were also substantially increased among small intestinal lamina
propria leukocytes (SI LPL) during SpA, accompanied by
increased intestinal levels of secreted GM-CSF (Fig. 3b).
Functionally, following triggering of SpA, prophylactic treat-
ment of SKG mice for ~7 weeks with anti-GM-CSF antibody
induced a striking decrease in LT-HSCs and MPPs in the BM
compared to treatment with isotype control (Fig. 3c), confirming
the GM-CSF responsiveness of HSPCs at early stages. Examining
the effect of GM-CSF blockade on progenitors downstream of
HSCs and MPPs, we observed decreased GMPs but increased
CLPs, and a less substantial increase in GMP:MEP ratio
associated with arthritis (Fig. 3d). Although total BM cellularity
was not affected by anti-GM-CSF treatment (Supplementary
Fig. 3a), HSPC changes induced by GM-CSF inhibition were
accompanied by a significant reduction in neutrophils and
increase of erythroid cells and B cells (Fig. 3e).
At peripheral sites, the myelopoiesis inhibition induced by
GM-CSF blockade was followed by a substantial decrease in
intestinal and articular neutrophil invasion (Fig. 3f). Strikingly,
these changes were accompanied by significant ameliorations in
the histological and clinical scores of arthritis (Fig. 3g), marked
decreases in enthesitis-associated ankle thickening (Fig. 3g) and
new bone formation (Supplementary Fig. 3b), and inhibition of
the bone surface:volume ratio increase (Fig. 3g), highlighting an
anti-GM-CSF-mediated reduction in inflammation-associated
bone damage26. Similarly, in the intestine, mice treated with
anti-GM-CSF exhibited a significant amelioration in enteritis and
weight loss compared to isotype control treated mice (Fig. 3h and
Supplementary Fig. 3c), highlighting the pathogenic role of GM-
CSF in the development of the various symptoms of SpA. Of note,
although the receptor subunit encoded by Csf2rb is common to
receptors for GM-CSF, IL-3, and IL-5, treatment with anti-IL-3 or
anti-IL-5 blocking antibodies did not inhibit disease (Supple-
mentary Fig. 3d).
Considering potential clinical applications, we tested whether
starting GM-CSF treatment only after the apparition of the first
clinical sign of arthritis would prevent disease progression. Mice
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Fig. 2 HSC and MPP upregulate myelopoiesis associated genes in SpA. a–c In three separate experiments, mice (n= 8 per group) were injected with
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ARTICLE NATURE COMMUNICATIONS | https://doi.org/10.1038/s41467-019-13853-4
4 NATURE COMMUNICATIONS |          (2020) 11:155 | https://doi.org/10.1038/s41467-019-13853-4 | www.nature.com/naturecommunications
treated with an isotype control progressed to develop severe
arthritis, while therapeutic injections of anti-GM-CSF starting
from day 9 during ~3 weeks either stabilized or reduced the
clinical score of arthritis (Fig. 3i).
EMH occurs inside inflamed joints. One obvious extra-articular
manifestation associated with systemic inflammation in SpA was
splenomegaly (Fig. 1b), presaging the possible development of
extramedullary hematopoiesis (EMH) during disease. In health,
the majority of HSPCs reside in the BM but some recirculate in
the blood and can accumulate in peripheral tissues during
infection, producing inflammatory myeloid cells locally to con-
tribute to immune defense27,28. In SKG mice, splenocyte numbers
were ~twofold increased during disease (Fig. 4a). Although the
percentage of GMPs among splenocytes was very low at steady
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state, it was increased ~fourfold in SpA (Fig. 4a). Using a func-
tional assay, we found that this increase in GMPs was mirrored by
significantly higher numbers of CFU-GM derived from spleno-
cytes of arthritic compared to healthy SKG mice (Fig. 4a), and a
marked enrichment in splenic neutrophils (Fig. 4b).
As the inflamed joints in SKG mice are severely infiltrated by
neutrophils and as EMH was occurring in spleen, we postulated
that EMH might also develop directly inside the inflamed joints.
Lin−cKit+ progenitors were, as expected, barely detectable in the
soft tissue of uninflamed paws, but analysis of cells isolated from
arthritic paw joints revealed the emergence of a GMP population
with inflammation (Fig. 4c). This previously unrecognized
phenomenon in chronic arthritis was substantiated by the high
proliferation rate of GMPs accumulating in the inflamed joints,
two thirds of articular GMP being Ki67+ (Fig. 4c).
To confirm that articular GMPs had the potential to contribute
locally to myeloid cell accumulation, we next sought to assess
their functional capacity. GMPs isolated from arthritic joints and
cultured in a medium favoring myeloid cell differentiation
generated ~70% CD11bhigh myeloid cells in 4 days, which was
similar to GMPs isolated from the BM, albeit with a lower total
cell output (Fig. 4d). On average, ~60% of myeloid cells derived
in vitro from articular or BM GMPs were Ly6G+ neutrophils
(Fig. 4d), the remainder being CD11b+CD16/32+Ly6G− mono-
cytes/macrophages (Fig. 4d), while, as expected BM MEP or
articular LinnegcKitneg cells were not able to generate myeloid
cells (Supplementary Fig. 4a). Furthermore, GMPs isolated from
the joints gave rise to CFU-GM similarly to BM GMPs, whereas
LinnegcKitneg and mature neutrophils from the joints were
incapable of such clonogenic activity (Fig. 4e). Commensurate
with these in vitro observations, adoptive transfer of GMPs
isolated from the BM of CD45.1+ mice into SKG mice (CD45.2+)
confirmed that BM GMPs could migrate to inflamed joints and
expand locally to give rise to tissue-toxic neutrophils, as also
observed in the spleen (Supplementary Fig. 4b).
Since GM-CSF promoted experimental SpA, we next sought to
investigate the role of GM-CSF in EMH development during
disease. GM-CSF blockade significantly decreased percentages of
GMPs and neutrophils in the spleen compared with isotype
control treatment (Fig. 4f). Likewise, SKG mice treated with anti-
GM-CSF displayed a significant reduction in articular GMP
numbers and, functionally, a substantial decrease in CFU-GM
activity in the joints (Fig. 4g).
In sum, these results reveal a previously unappreciated emergence
of a highly proliferative and functional GMP population directly
inside the joints during chronic inflammatory arthritis. GM-CSF
was essential in promoting this articular EMH activity, which fueled
the generation of tissue-toxic neutrophils directly inside the joints.
MC contribute to GM-CSF production in SpA. We next aimed
to identify the main cellular sources of GM-CSF during disease.
The intestinal lamina propria, which is inflamed in a high pro-
portion of AS patients11 and in curdlan-triggered SKG mice, is a
major site of IL-23 production and a privileged location for Th17
cell and innate lymphoid cell (ILC) responses, which produce
GM-CSF during inflammation3,29–31. Importantly, cytokines
produced in the inflamed gut can reach systemic levels and
remotely influence BM hematopoiesis, as described during
intestinal infection32,33.
With this in mind, we examined by FACS the potential cellular
sources of GM-CSF in the intestine during SpA. Regarding the
relative contribution of innate versus adaptive immune cells in
inflammation, CD4 T-cell depletion revealed that these cells were
not absolutely required for the development of experimental SpA
(Supplementary Fig. 5a), fitting with the importance of innate
cells described in AS12,34. In addition, as ILC and myeloid cells
participate in the development of arthritic inflammation in SKG
mice35,36, we suspected a key role for innate cells in GM-CSF
production. Although lymphoid cells are recognized as the main
producers of GM-CSF25, our analysis revealed that some
intestinal Lin−Thy1− cells, i.e., non-T cells and non-ILC, were
also positive for GM-CSF (Fig. 5a). We hypothesized that MC,
which are abundant at mucosal sites37,38, were a possible
candidate for this undefined source of GM-CSF. Indeed, the use
of classical lineage markers does not identify MCs as they do not
express CD11b or Gr1. Fittingly, lin−ckit+FcERI+ MCs from the
intestine of inflamed mice expressed Csf2 (encoding GM-CSF),
even to a greater extent than CD4 T cells (Fig. 5b); this was also
observed in the joint (Fig. 5b). Using BM-derived MC (BMMC)
(Supplementary Fig. 5b), which secrete high levels of inflamma-
tory mediators39, including IL-6 after LPS stimulation, we
demonstrated in vitro that MCs could secrete GM-CSF upon
similar activation (Fig. 5c).
Next, we confirmed that a high proportion of intestinal
ckit+FcERI+ MC produced GM-CSF, to a similar extent as the
Thy1+IL7R+ ILC (Fig. 5d) that were described recently as a
major source of GM-CSF in our study of colitis31 and in the joints
in a model of rheumatoid arthritis (RA)36. Although arthritogenic
TNF was produced by similar proportions of T cells, ILCs, and
MCs, the percentage of GM-CSF+ cells was much greater among
MCs and ILCs than CD4 T cells during SpA (Fig. 5d). In
addition, in situ staining revealed that intestinal MCs were
significantly enriched in the inflamed SI and joints in SpA (Fig. 5e
and Supplementary Fig. 5d).
Therefore, besides ILCs and, to a lesser extent, CD4 T cells, our
findings uncovered MCs as an unappreciated source of the pro-
myeloid factor GM-CSF during SpA. We also showed that their
Fig. 3 GM-CSF drives BM myelopoiesis and organ inflammation in SpA. a Representative intracellular cytokine staining from CD4 T cells from popliteal
lymph nodes and paw joints of mice culled 5 weeks after SpA induction. Frequencies and absolute numbers of articular GM-CSF+ CD4 T cells in healthy
versus spondyloarthritic SKG mice; cells were incubated with brefeldin A, PMA and ionomycin before staining. b Absolute numbers of GM-CSF+ CD4
T cells in SI LPL and total GM-CSF protein in SI quantified by ELISA, n= 5 per group. c–h Curdlan-triggered SKG mice were treated for the entire duration of
the experiment (6–7 weeks) with anti-GM-CSF or isotype control antibodies and compared to healthy (steady state) SKG controls. c LSK staining and
frequencies of LT-HSCs and MPPs populations in BM. d GMP and MEP staining, GMP:MEP ratio, and frequencies of GMP and CLP populations in BM.
e Frequencies of neutrophils, erythroid cells and B cells in BM. f Staining and absolute numbers of neutrophils in joints (left) and SI (right). gMean arthritis
scores (n= 7 mice in each group), histological arthritis scores and increase in ankle size (left). Representative µCT scans of isotype or anti-GM-CSF
antibody treated SpA mice and changes in bone surface to volume ratio pooled from two independent experiments (right). Scale bars= 1 cm.
h Representative photomicrographs of small intestinal sections (magnification ×4 and ×10) and histological enteritis scores. Scale bars= 1 cm (left panels)
and 200 µm (right panels). i Clinical arthritis score of mice that received isotype or anti-GM-CSF antibody injections starting 9 days after injection of
curdlan, when the first clinical signs of arthritis appeared (n= 7 mice in each group). Groups were compared using the Wilcoxon matched-pairs signed
rank test. Data are representative of two independent experiments (a–h). Dots represent individual mice; horizontal bars indicate mean. Groups were
compared using Mann–Whitney U tests unless noted otherwise. Source data are provided as Source Data file.
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numbers were increased during disease, constituting a potential
long-lasting source of local and systemic GM-CSF.
MC are activated and their inhibition dampens SpA. Previous
studies of human inflammatory arthritis have described MCs as
being activated in target organs and releasing inflammatory
mediators such as IL-17A and TNF in AS and RA40,41. Because
we found that MCs were increased in SpA and produced GM-
CSF, we explored their contribution to disease development.
First, we confirmed our observation of increased MC numbers
based on histological analysis of intestinal tissue by FACS, finding
a significant increase in MC percentage among SI LPL of
spondyloarthritic mice compared to uninflamed controls, and an
increase of approximately fivefold in total numbers (Fig. 6a).
Second, we found that intestinal MCs had an activated phenotype
during disease, with increased surface expression of FcγRII/III
and IL-33R compared to MCs from healthy mice (Fig. 6b). Of
note, splenic MC numbers were also increased during SpA
(Supplementary Fig. 5e).
% of total cells : 0.097
GMPGMP
% of total cells : 0.016
a
c
Spleen
3.3 17
CD
16
/3
2
CD34
Healthy Arthritic
Healthy Arthritic
0
4
8
12
Total cell number
p = 0.002
×
10
7  
ce
lls
Gate : Lin– cKit+ Sca1–
Gate : Lin– cKit+ Sca1–
Gate : Lin– cKit+ Sca1–
Lin– cKit–
Gate : Lin– cells
Ki
-6
7
c-Kit Gate : GMP
Inflamed joint
Ki
-6
7
SSC
20
8034
66
Healthy Arthritic
CD
16
/3
2
CD34
Joint
Healthy Arthritic
0.00
0.05
0.10
0.15
0.20
0.25
0.30
%
 to
ta
l c
el
ls
p = 0.002
GMP (Joint)
Healthy Arthritic
0.00
0.05
0.10
0.15
0.20
GMP
p = 0.002
%
 G
M
P/
to
ta
l c
el
ls
d
Ly
-6
G
CD16/32
BM GMP Joint GMP
Neutrophils Neutrophils
Gate : Live CD11b+ cells
BM GMP Joint GMP
Neutrophils
/CD11b+ (%)
%
 o
f t
ot
al
 c
el
ls
e
Fc
εR
I
CD11b Gate : Live cells
BM GMP Joint GMP
82 79
Myeloid cells Myeloid cells
Myeloid culture output:
fBM GMP Joint GMP
CFU 
assay
(sorted
cells)
Joint Lin– cKit– cells Joint neutrophils
6246
53.6 37.2
g
%
 o
f t
ot
al
 c
el
ls
%
 o
f t
ot
al
 c
el
ls
0.00
0.05
0.10
0.15
0.20
0.25
GMP
p = 0.001 p = 0.0006
Steady
state
Isotype Anti-GM-CSF
Curdlan
Isotype Anti-GM-CSF
% of total cells : 0.230 % of total cells : 0.040
GMP GMP
Joint
CD
16
/3
2
CD34
0
5
10
15
20
p = 0.0006p = 0.001
Steady
state
Isotype Anti-GM-CSF
Curdlan
×
10
3  
ce
lls
Spleen
Joint
CFU
assay
(total
joint
cells)
Steady
state Isotype Anti-GM-CSF
Curdlan
0
4
8
12
16 p = 0.002 p = 0.0006
p = 0.03
Steady
state
Isotype Anti-GM-CSF
Curdlan
N0 CFU-GM (Joint)N0 GMP (Joint)
ArthriticHealthy
0
5
10
15
20
25
30
p = 0.001
Spleen
Myeloid output:
b
5.9 19
Ly
-6
G
CD11b Gate : live cells
Healthy Arthritic
GMPGMP
Co
lo
ni
es
 p
er
 1
 ×
 1
05
 
ce
lls
Co
lo
ni
es
 p
er
  3
 ×
 1
05
 
ce
lls
N0 CFU-GM
BM GMP Joint GMP
0
20
40
60
80
100
CD11b+ cells (%)
%
 o
f t
ot
al
 c
el
ls
Total cells Myeloid culture:total cell output
BM Joint BM Joint
0
5000
10,000
15,000
20,000
25,000
GMP
Steady
state
Isotype Anti-GM-CSF
Neutrophils
p = 0.002p = 0.01
Curdlan
0
10
20
30
40
0
20
40
60
80
100
103
103
102
101
100
100 101 102 103 100 101 102 103
104
105
104
103
102
101
100
100 101 102 103 104 100 101 102 103 104
105
104
103
–103
–103 –103103 104 105 103 104 1050 0
0
6.38 3.59
104
103
–103
–103 103 104 1050 –103 103 104 1050
0
104
0
0
104
5.84E–3
0.21
103
102
101
100
0 200 400 600 800 1.0 K
103
102
101
100
100 101 102 103 104
105
104
103
–103
–103 103 104 1050 –103 103 104 1050
0
102
101
101 102 103 101 102 103
Fig. 4 Extramedullary hematopoiesis occurs inside inflamed joints. a–c Spondyloarthritic mice were culled (week 5) and compared with healthy SKG
mice. a Total splenocyte numbers, GMP staining, frequencies of GMPs and CFU-GM numbers in spleen. b Representative neutrophil staining in spleen.
c GMP staining, Ki-67 staining of GMP cells and control Lin− cells, and frequencies of GMPs in paw joint single cell suspension. d Staining, frequencies of
CD11b+ myeloid cells cultured from GMPs isolated from inflamed BM and joints and absolute numbers of myeloid cells following culture of indicated
starting populations (left). Neutrophil staining following culture of GMPs from BM or joint and frequencies among myeloid cells (right). Bars represent
mean and SEM of two independent experiments. e Representative photomicrographs of CFU-GMs formed from indicated cell populations. Scale bars=
500 µm. f GMP and neutrophil frequencies in spleens of healthy, isotype, or anti-GM-CSF antibody treated mice. g GMP staining and absolute numbers in
joints at week 6–7 (left). Representative photomicrographs and numbers of CFU-GMs obtained from joint cells of indicated groups (right), scale bars=
500 µm. Data are representative of three (a–c) or two (e–g) independent experiments. Groups were compared using Mann–Whitney U tests. Source data
are provided as Source Data file.
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We next investigated the effect of MC inhibition on
development of SpA. MC release various inflammatory com-
pounds via two main distinctive pathways, i.e., degranulation of
preformed compounds present in primary granules (e.g.,
histamine and prostaglandins) or release of de novo synthesized
mediators (e.g., cytokines and chemokines)42. In our study, we
used cromolyn, a well-described MC stabilizer, which inhibits
MC degranulation and cytokine release43,44. Daily IP injection
with cromolyn significantly dampened the SpA-associated
increase in GM-CSF+ MC numbers, in the intestine and spleen
(Fig. 6c), compared to PBS injection (Fig. 6d). Inhibition of MC
activation was accompanied by decreased splenic and articular
GMP numbers (Supplementary Fig. 5f) and also decreased
neutrophil invasion of target organs (Fig. 6e). MC inhibition
during development of SpA resulted in decreased paw and ankle
swelling and diminished clinical score of arthritis (Fig. 6f).
In summary, inhibition of MC activity in SpA led to reduced
numbers of GM-CSF-producing MCs and decreased joint
inflammation, highlighting the contribution of MCs to the
inflammatory network in SpA.
IL-33 can promote GM-CSF production by MC during SpA.
We next resolved to identify potential triggers of MC activation
and GM-CSF secretion in SpA. MCs can detect and respond to
various inflammatory stimuli in peripheral tissues, including
alarmins released upon tissue damage or mechanical stress, e.g.,
IL-33 and ATP39. IL-33 was of particular interest because its
intestinal and joint levels were substantially increased in spon-
dyloarthritic mice compared to uninflamed controls (Fig. 7a), as
reported in the blood and intestine in AS patients compared to
healthy controls45,46. Moreover, IL-33 promotes GM-CSF secre-
tion by ILCs in mouse and human36,47, and St2, which encodes
IL-33R, was expressed at higher levels in MCs compared to other
major immune cell types (Supplementary Fig. 6a). BMMCs
likewise expressed high levels of IL-33R (Fig. S5c), as did MCs
from intestinal tissues (Fig. 6b). In terms of MC responsiveness to
IL-33, although it did not activate degranulation by BMMC
as monitored by release of the granule component
β-hexosaminidase (Supplementary Fig. 6b and ref. 48), we
demonstrated that IL-33 stimulation induced abundant GM-CSF
secretion (Fig. 7b), in addition to its previously reported IL-6
promoting effect39. Increased GM-CSF levels were also detected
intracellularly by FACS in activated BMMC following IL-33
exposure (Supplementary Fig. 6c). Of note, Cromolyn, which can
inhibit cytokine secretion by MC43,44, decreased IL-33 mediated
GM-CSF release by BMMC (Supplementary Fig. 6d).
In light of these results, we hypothesized that IL-33 might
promote dysregulated hematopoiesis and chronic inflammatory
arthritis by stimulating GM-CSF secretion from activated MC.
Importantly HSCs, MPPs, and GMPs do not express the IL-33R49
and therefore cannot respond to any direct effect of IL-33. To
evaluate IL-33 effects in SpA, we treated curdlan-triggered SKG
males, which develop less severe disease than females16, with
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twice weekly IL-33 injections for 5 weeks (Fig. 7c). This treatment
led to increased levels of secreted GM-CSF in inflamed target
organs (Fig. 7d). As reported before, IL-33 injections induced
goblet cell hyperplasia and abundant intestinal mucus produc-
tion50, which precluded reliable isolation of viable SI LPL cells.
Study of the MC response to IL-33 by FACS was possible in the
spleen however, where MCs may also become activated and
increased during inflammation, as reported in food allergy and
sepsis51,52. With SpA, MCs were significantly expanded in the
spleen of IL33-injected SKG mice compared to PBS-treated
controls (Fig. 7e) and, remarkably, IL-33 treatment induced a
substantial increase in GM-CSF+ cell percentage among MCs,
from ~20% to ~60% (Fig. 7f). These IL-33-mediated changes in
GM-CSF production were accompanied by a significant increase
in BM LT-HSCs and MPPs (Fig. 7g) and biased differentiation
toward myeloid cells. Indeed, a substantial increase in GMPs and
neutrophil percentages occurred in the BM of IL33-treated mice
compared to controls (Fig. 7g) even though the total BM
cellularity was unchanged (Supplementary Fig. 6e). In addition,
IL-33 injections promoted EMH because splenic and articular
GMP numbers were substantially increased, with accompanying
neutrophil expansion at both sites (Fig. 7h). Clinically IL-33
injections twice weekly with 1 µg of IL-33 induced a significant
worsening in the clinical score of arthritis and the joint swelling
severity (Fig. 7i), which was also observed with a twofold lower
dose of IL-33 (Supplementary Fig. 6f).
Neutralization of IL-33 activity by ST2-Fc treatment did not
affect levels of TNF produced by intestinal MC (Supplementary
Fig. 6g), but resulted in a decrease in GM-CSF production
(Fig. 7j), highlighting a promoting effect of endogenous IL-33 on
GM-CSF secretion by MC. Although ST2-Fc treatment signifi-
cantly decreased joint swelling and arthritis at early and
intermediate time points compared to mice injected with an
isotype control (Fig. 7k and Supplementary Fig. 6h), the
significance of this protective effect was lost at the final time
point (Fig. 7k). This progressive loss of effect could be mediated,
for example, by a compensatory effect of other cytokines able to
promote GM-CSF secretion by MC, as described for TNF and IL-
1β53. In line with the observed pathogenic role of GM-CSF in
SpA, aggravation of arthritis and increased accumulation of GMP
and neutrophils in inflamed joints induced by IL-33 injections
were prevented if mice were co-injected with anti-GM-CSF
(Fig. 7l and Supplementary Fig. 6i).
Collectively, our findings show that IL-33, of which endogen-
ous levels were increased in SKG mice during SpA, has the
capacity to promote the secretion of GM-CSF by MC, overall
resulting in exacerbated HSC activity, biased differentiation
toward GMP during SpA, and increased neutrophil invasion
and inflammation of the joints.
Discussion
HSCs have recently emerged as an integral part of the immune
response and as central sensors of inflammatory stimuli during
infectious and chronic inflammatory diseases9. Furthermore,
prolonged exposure to inflammatory stimuli during chronic dis-
eases may have long-lasting effects on the nature of the BM cell
output through epigenetic modifications in HSPCs54,55.
Here, we investigated the regulation of HSPCs in the context of
chronic inflammatory arthritis to gain a greater understanding of
the complex immune network in SpA. We observed that the
differentiation of HSCs was markedly skewed toward GMPs,
resulting in increased neutrophil production, which was mirrored
by decreased lymphopoiesis and erythropoiesis. RNAseq analysis
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of HSCs and MPPs revealed a bias toward myeloid gene
expression during SpA, e.g., Csf2rb. Early stage responsiveness of
HSCs and MPPs to GM-CSF was demonstrated in vitro and
in vivo. Its blockade in curdlan-triggered SKG mice significantly
decreased myelopoiesis in the BM and at extramedullary sites, as
well as intestinal and articular inflammation.
Beyond their paracrine and autocrine functions, cytokines
can exert effects on distant organs, for example the BM, when
they are produced at high levels in inflamed peripheral tissues
during autoimmune or infectious diseases15,32,56. Approxi-
mately, 50–60% of AS patients develop subclinical intestinal
inflammation11, and the raised levels of various inflammatory
cytokines observed in the intestine and blood of AS
patients29,45 could conceivably affect BM activity. Accordingly,
while there have been no published studies describing hema-
topoiesis changes in the BM during AS, development of the
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disease is associated with increased blood neutrophil and
decreased lymphocyte concentrations57, such that the neu-
trophil: lymphocyte ratio has been used as an indicator of
disease severity58.
IL-33 is increased in the intestine and blood of AS patients
compared to healthy controls45,46, which echoes our observations
in spondyloarthritic mice. IL-33R is expressed by MCs and type 2
ILCs59, contrary to GMPs, MPPs and HSCs49, rendering the latter
cell types unresponsive to any direct effect of IL-33. Epithelial
cells and fibroblasts release IL-33 in response to infection and
tissue damage, which promotes cytokine secretion (e.g., IL-5, IL-
9, and IL-13) by IL-33R-expressing leukocytes59. Besides these
type 2 cytokines, our results indicate that IL-33 primes MCs to
secrete GM-CSF, a cytokine often associated with type 17
immune responses25 and, in our hands, acts directly on HSPCs to
promote myelopoiesis in the SKG model of SpA, which is IL-17
and IL-23 dependent60.
We previously observed dysregulated HSC activity, character-
ized by increased myeloid cell output, in murine models of
colitis2. Similar phenomena were reported in mice with lupus4
and atherosclerosis61, revealing dysregulated HSC activity as a
shared pathophysiological mechanism operating in diverse
chronic inflammatory diseases. Interestingly, although BM sam-
ples from human patients suffering from chronic inflammatory
diseases are scarce, people with atherosclerosis have increased
CFU-GM activity in BM compared to matched controls5, and RA
patients have increased production of neutrophils but decreased
production of erythroid cells in their BM62,63.
GM-CSF was pathogenic in the SKG model of SpA and is
emerging as a central player in chronic inflammatory diseases,
including mouse models of multiple sclerosis25, colitis2 and
RA24,36. In a zymosan-induced model of interstitial lung disease
associated with arthritis development, GM-CSF blockade in SKG
mice prevented and ameliorated lung and joint inflammation,
while IL-17A blockade had only a minor effect on disease
severity64. Interestingly, in our study GM-CSF not only drove
dysregulated hematopoietic activity in the BM of spondylarthritic
mice but also did so at extramedullary sites. We report the
unexpected accumulation of highly proliferative and functional
GMP directly in the inflamed joints of arthritic mice, which
contributed to the accumulation of neutrophils in the joints
during SpA. Although EMH is poorly understood, HSPCs were
demonstrated to accumulate in various peripheral tissues in
response to infection and generate inflammatory myeloid cells
locally, e.g., granulocytes27,28. This phenomenon can contribute
to fight infection28, but is potentially detrimental to the host
during non-resolving inflammatory diseases. For example, in
atherosclerosis, splenic GMPs contribute to increased production
of circulating monocytes and subsequent inflammation in
atheromatous plaques6.
ILCs and T cells are well-known sources of GM-CSF, as
observed in AS65. Our data indicate that MCs also produce GM-
CSF in experimental SpA, which builds on previous work
showing that MCs are present in increased numbers in the
synovial membrane of patients with SpA and RA, where they
produce IL-17A and TNF40,41. In addition, MC were detected in
the synovial fluid in a higher proportion of SpA patients com-
pared to patients with other forms of arthritis66. Similarly to our
observations in mice, a promoting effect of IL-33 on GM-CSF
secretion by human MC has been reported in several studies48,67,
supporting the potential relevance of the MC-mediated IL-33/
GM-CSF axis to the inflammatory response to humans. Conse-
quently, MCs may represent a promising therapeutic target for
SpA, with a recent pilot study suggesting this approach could be
safe and effective68. In addition, our work highlights the potential
benefits of antibody-mediated blockade of GM-CSF for SpA. Such
treatment is safe in humans and has generated encouraging
results in phase II clinical trials for RA69.
Overall, our work sheds light on the complex inflammatory
network in SpA, highlighting an underappreciated role for HSPCs
in the co-ordination of inflammatory pathology at locations
distant from the BM.
Methods
Mice and model of disease. SKG mice (BALB/c-zap70W163C), which are arthritis-
prone because of a point mutation in ZAP-7017, were bred and maintained under
specific pathogen-free (SPF) conditions in licensed animal facilities at the Uni-
versity of Oxford. Mice were age matched across different treatment groups.
Where indicated, SpA was induced in 8–12-week-old SKG females by a single
intraperitoneal (IP) injection of 0.3 mg of the microbial polysaccharide curdlan
(Wako Chemicals USA, Inc.), which is a β-1,3-Glucan. Curdlan-injected
spondyloarthritic mice (“arthritic”) were compared to PBS-injected SKG mice
(“healthy”), as unmanipulated or PBS-injected SKG mice do not develop arthritis
under SPF conditions16. Although we did not investigate spinal inflammation in
our study, this model also recapitulates the spondylitis phenotype characteristic of
AS16.
Disease was monitored and scored weekly. The scoring was done as follows:
0= no swelling or redness, 0.5= swelling or redness of digits and mild swelling
and/or redness of wrists or ankle joints, 1=mild swelling of wrist and ankle joints,
2=moderate swelling of wrist and ankle joints, 3= substantial swelling of wrist
and ankle joints, not inhibiting normal mobility, feeding and drinking. Scores of
forepaws and hind paws were totaled for each mouse. Paw thickness in the front
paws, hind paws and ankles was also measured using dial-type callipers (Diatest
Ltd., UK). Changes in paw or ankle size were calculated by subtracting the initial
cumulated size of all paws or ankles from the cumulated size of all paws or ankles
at the indicated time points.
All procedures involving mice were conducted according to the requirements of
the UK Animals (Scientific Procedures) Act 1986. Experiments were approved by
the University of Oxford Animal Welfare Ethical Review Body (Home Office
Project License 30/3218).
In vivo treatments. Anti-GM-CSF (clone MP1-22E9) and isotype control anti-
body (clone 2A3) were purchased from Bio X Cell. Age matched female SKG mice
were injected IP with either anti-GM-CSF antibody (0.25 mg) or isotype control
antibody (0.25 mg) either on the day before curdlan injection and twice weekly for
Fig. 7 IL-33 can promote GM-CSF production by mast cells during SpA. a IL-33 protein levels from joints and SI of healthy and spondyloarthritic mice,
n= 13 mice per group. b BMMC were stimulated with PBS or IL-33 for 16 h and secreted IL-6 and GM-CSF quantified by ELISA. Error bars= SEM of 3
independent experiments. c–i SpA-triggered male SKG mice were injected IP twice weekly with PBS or 1 µg of rIL-33. c Experimental protocol. d GM-CSF
protein levels from joints and SI from PBS or IL-33 treated mice, n= 7 mice per group. e Frequencies and absolute numbers of splenic MC. f Staining of
intracellular cytokines (compared to GM-CSF FMO control) and frequencies of GM-CSF+ cells among splenic MCs. g Frequencies of LT-HSCs and MPPs in
BM (left). Staining of GMPs and MEPs in BM (middle). Frequencies of GMPs and neutrophils in BM (right). h Absolute numbers of GMP and neutrophils in
spleens (left) and joints (right). Dots represent individual mice; horizontal bars indicate mean. i Mean arthritis scores (n= 7 mice in each group) and
increase in ankle thickness. j–k SKG females were injected with ST2-Fc or control Fc fragment for 5 weeks after injection of curdlan. j Frequency of
GM-CSF+ mast cells in SI of Fc control- and ST2-Fc-treated mice after 5 weeks. k Change in paw size (left) and clinical arthritis score (right) in Fc control-
and ST2-Fc-treated mice after 2 (top) or 5 (bottom) weeks. l SKG males were injected with curdlan then IL-33, with or without isotype or anti-GM-CSF
antibodies. Dots represent individual mice; horizontal bars indicate mean. Clinical arthritis score (left) and change in ankle thickness (right) after 4 weeks.
Data are representative of three independent experiments (a−i) or pooled from two independent experiments (k). Groups were compared using
Mann–Whitney U tests. Source data are provided as Source Data file.
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the duration of the experiment (6–7 weeks) or 9 days after disease triggering and
twice weekly until day 28.
Age matched SKG males were injected IP with recombinant murine IL-33 (1 µg;
BioLegend) or PBS on the day before curdlan injection. IL-33 (0.5 and 1 µg) or PBS
was administered twice weekly for the duration of the experiment (5 weeks).
Notably, curdlan-triggered SKG males develop SpA more slowly and less severely
than SKG females16. In a further experiment, male SKG mice were injected with
curdlan then IL-33 (0.5 µg/injection) twice weekly, with anti-GM-CSF antibody
(0.25 mg) or isotype control (0.25 mg) twice weekly for 4 weeks.
In a separate set of experiments, female SKG mice triggered for SpA
development were injected IP daily either with the MC stabilizer cromolyn sodium
(200 mg/kg; Sigma-Aldrich) dissolved in PBS or with PBS only for the duration of
the experiment (28 days).
In a further experiment, female SKG mice were injected with curdlan then, after
1 week, with recombinant murine GM-CSF (2 μg; Peprotech) or PBS every 2 days
for a total of 4 injections.
Female SKG mice were injected with curdlan, then ST2-Fc fragment (mouse
ST2-mouse IgG1-Fc, Medimmune) or with a control mouse IgG1 (NIP228,
Medimmune), both at 0.3 mg per IP injection three times weekly for 5 weeks.
Female SKG mice were injected with curdlan then anti-IL-5 antibody (Bio X
Cell, clone TRFK5) or isotype (clone HPRN), both at 0.3 mg per injection IP three
times weekly for 4 weeks. In a separate experiment, female SKG mice were injected
with curdlan then anti-IL-3 antibody (Bio X Cell, clone MP2-8F8) or isotype (clone
HPRN), both at 0.375 mg per injection IP twice weekly for 4 weeks.
Female SKG mice were injected with curdlan and anti-CD4 depleting antibody
(Bio X Cell, clone YTS 191) or isotype (clone LTF-2), both at 100 mg per injection
IP twice weekly for 4 weeks starting 2 days before curdan injection. The efficacy of
the CD4 T-cell depletion was assessed using a different anti-CD4 clone (RM4-5).
Histological scoring of arthritis and enteritis. For histology, mice were culled
and hind paws and sections of SI (duodenum, jejunum, and ileum) were fixed in
4% formalin before embedding in paraffin. The paws were decalcified with 10%
neutral buffered EDTA for 4 weeks and then embedded in paraffin. Paraffin-
embedded sections were cut (5 μm) and stained with hematoxylin and eosin;
inflammation was scored in a blinded fashion. Histopathological severity of
arthritis was scored in the tarsometatarsal, metatarsophalangeal, and inter-
phalangeal joints by microscopy in a blinded fashion. The histological severity of
arthritis was graded as follows: 0= normal; 1=minimal synovitis, cartilage loss,
and bone erosions limited to discrete foci; 2= synovitis and erosions present but
normal joint architecture intact; and 3= synovitis and extensive erosions present
and joint architecture disrupted. The data are shown as the average score from the
three joints for each mouse. Inflammation of the SI (epithelium, lamina propria,
and submucosa) was scored in a blinded fashion using a previously described
scoring system2. In indicated experiments, sections of SI and paws were stained
with toluidine blue to visualize MC. MC were quantified by counting all cells in the
section (SI) or by taking the average of cells counted in 8 × 20 objective fields in the
periarticular regions of the tarsometatarsal and proximal interphalangeal joints of
each mouse (paw).
Cell isolation from SI for FACS analysis. Mice were culled and SI were removed
and washed in sterile PBS supplemented with 0.1% bovine serum albumin (BSA).
SI was cut into sections and then opened longitudinally. Excess mucus was
removed. Tissue was incubated in RPMI 1640 supplemented with 5% fetal calf
serum (FCS) and 2 mM EDTA on a shaking incubator (150 rpm) heated to 37 °C
for 20 min. This EDTA incubation was repeated for 20 min, after which, pieces of
tissue were incubated in RPMI 1640 supplemented with 5% FCS at room tem-
perature for 10 min without shaking. Pieces of tissue were then transferred to new
tubes and digested in RPMI 1640 supplemented with 10% FCS, DNaseI (40 U/ml;
Sigma-Aldrich) and collagenase VIII (0.25 mg/ml; Sigma-Aldrich) for 30 min at 37
°C on a shaking incubator. Tissue was filtered through a 70 µm strainer and
centrifuged. Digested tissue was separated by centrifugation on a 30%/40%/70%
Percoll gradient (GE Healthcare), centrifuging at 1800 rpm for 20 min with no
brake. Cells at the 40%/70% interface were collected as the leukocyte-enriched
fraction, i.e., SI LPL.
Cell isolation from spleen and BM for FACS analysis. Spleens, femurs and tibiae
were harvested into PBS supplemented with 0.1% BSA. Spleens were passed
through a 70 μm filter. The single cell suspension was centrifuged and resuspended
in 1 ml red blood lysis solution for 2 min at room temperature. Lysis was
stopped by addition of ice-cold PBS with 0.1% BSA. Cells were centrifuged and
resuspended in PBS with 0.1% BSA before being stained for FACS analysis. BM cell
suspensions were prepared by flushing the marrow from femur and tibia and were
resuspended in PBS with 0.1% BSA. Cells were centrifuged and re-suspended,
before staining for FACS analysis.
Cell isolation from paw joint for FACS analysis. The skin was removed from one
hind paw and the paw was cut into four pieces. Pieces of tissue were incubated in 1
ml of RPMI 1640 supplemented with DNAse I (0.1 mg/ml) and Liberase (Roche,
0.3 mg/ml) for 90 min at 37 °C. Digested soft tissue from the paw joint was then
passed through a 70 µm strainer to obtain a single cell suspension which was
stained for flow cytometry.
Flow cytometry and cell sorting. Single-cell suspensions of desired tissues were
obtained as described above. In total, 1–2 × 106 cells were stained with fixable
viability dye (BioLegend) for 15 min in the dark at room temperature. Cells were
centrifuged and incubated with unlabeled anti-CD16/32 to block nonspecific
staining (unless anti-CD16/32 was in the staining panel), and were then stained
with surface antibodies in PBS with 0.1% BSA for 30 min in the dark at 4 °C. Cells
were centrifuged and fixed for 15 min using fixation solution (Cytofix/Cytoperm,
BD) at 4 °C. Cells were centrifuged and re-suspended in PBS with 0.1% BSA and 2
mM EDTA.
For intracellular staining, cells were first incubated in RPMI 1640 with 10% FCS
and 5 µg/ml brefeldin A with or without PMA (5 ng/ml) and ionomycin (500 ng/
ml) for 3 h at 37 °C and 5% CO2. Cells were stained with a viability dye and for
surface antigens as above for 30 min. After fixation, cells were permeabilized by
addition of cytoperm solution for 15 min followed by addition of intracellular
antibodies diluted in cytoperm solution for 45 min at 4 °C in the dark. Cells were
centrifuged and resuspended in PBS with 0.1% BSA and 2 mM EDTA before
acquisition.
The following monoclonal antibodies were used for flow cytometry analysis,
with the name of the clone indicated in brackets: anti-CD45 (clone 30-F11), anti-
CD11b (M1/70), anti-Ter119 (Ter119), anti-Gr-1 (RB6-8C5), anti-CD3 (17A2),
anti-CD4 (clone RM4-5 or clone GK1.5), anti-NKp46 (29A1.4), anti-CD11c
(N418), anti-B220 (RA3-6B2), anti-FcεR1 (MAR-1), anti-Ly-6G (1A8), anti-Ly6C
(HK1.4), anti-F4/80 (BM8), anti-CD16/32 (i.e., FcγRII/III; clone 2.4G2), anti-
CD90.2 (30-H12), anti-CD117 (2B8), anti-CD34-FITC (RAM34), anti-Ly-6A/E
(i.e., Sca-1; clone D7), anti-CD150 (TC15-12F12.2), anti-CD48 (HM48-1), anti-
GM-CSF (MP1-22E9), and isotype control: Rat IgG2a (RTK2758), anti-TNF-α
(MP6-XT22), anti-pro-IL-1β (NJTEN3), anti-IL-33Rα (i.e., ST2; clone DIH9), anti-
Ki67 (16A8), anti-IL-7R (A7R34), anti-CD64 (i.e., FcγRI; clone X54-5/7.1).
Antibodies were purchased from BioLegend, BD Biosciences or eBioscience. Viable
cells were identified as unstained with Zombie Aqua or Green (BioLegend).
Samples were acquired on an LSR II or LSR-Fortessa (Becton Dickinson) and
analyzed using Flowjo Software (TreeStar Inc). Cell sorting was performed using a
FACS ARIA III (Becton Dickinson).
Quantitative real-time PCR. Total RNA was isolated from sorted cells using the
RNeasy micro kit (QIAGEN) and 50 ng of total RNA was reverse transcribed using
the High-Capacity cDNA Reverse Transcription Kit (Affymetrix eBioscience).
Total RNA from SI was isolated by tissue disruption using lysis beads in RLT buffer
and the Precellys24 homogenizer. RNA was isolated using the RNeasy Mini Kit
(QIAGEN) according to manufacturers’ instructions. Quantitative RT-qPCR was
performed using Taqman assays and PrecisionFast Mastermix (PrimerDesign) on a
ViiA7 384-well real-time PCR system. All expression levels were normalized to an
internal reference gene (Hprt) and calculated as 2−(CT Hprt-CT gene). Real-time
qPCR was performed in duplicate and using the following Taqman primers
(Thermo Fisher Scientific): Csf2 (Mm01290062_m1), Tnf (Mm00443258_m1),
Hprt (Mm03024075_m1), Il6 (Mm00446190_m1), Il23 (Mm00518984_m1), Il1b
(Mm00434228_m1), and St2 (Mm00516117_m1).
RNA sequencing. SpA was induced in 8–10-week-old female SKG mice by injecting
curdlan IP and mice were culled 5 weeks after disease triggering. Healthy or
spondyloarthritic SKG mice were culled and LT-HSCs, ST-HSCs, MPPs, and GMPs
were FACS-sorted from BM directly into RLT buffer containing β-mercaptoethanol.
LT-HSCs were defined as Lineage−, c-kit+, Sca-1+, CD34−, CD150+, CD48−, ST-
HSCs were defined as Lineage−, c-kit+, Sca-1+, CD34+, CD150+, MPPs were
defined as Lineage−, c-kit+, Sca-1+, CD34+, CD150−, CD48+, and GMPs were
defined as Lineage−, c-kit+, Sca-1−, CD34+, CD16/32hi. Of note, ST-HSC are also
referred to in other publications as “MPP1-2” and MPP as “MPP3-4”19. RNA was
isolated using the RNeasy Micro Kit (QIAGEN) according to manufacturers’
instructions. cDNA was prepared using the SMARTer protocol (Clontech) and
sequencing libraries prepared using the NEBNext Ultra protocol (NEB). Libraries
were subject to 75 bp paired-end sequencing (Illumina HiSeq 4000) to an average
depth of 11.2 million read pairs per sample.
Computational analysis of RNA sequencing. Sequence reads were aligned to the
mouse genome with Hisat2 (version 2.0.4) using a “genome_trans” index built
from the mm10 release of the mouse genome and Ensembl version 83 annotations
(two-pass strategy to discover novel splice sites; with parameters: –dta and –score-
min L,0.0,−0.2). Mapped reads were counted using featureCounts (Subread version
1.5.0; Ensembl version 83 annotations; default parameters). FPKMs were estimated
with cuffquant (Cufflinks version 2.2.1; Ensembl version 83 annotations; with
parameters: –multi-read-correct –no-effective-length-correction –max-bundle-
frags 2000000 –max-mle-iterations 10000 –frag-bias-correct). Upper quartile
normalized FPKM values were computed using cuffnorm (Cufflinks version 2.2.1;
with parameters: –compatible-hits-norm library-norm-method quartile). Differ-
ential gene expression analysis was performed using DESeq2 (dispersions estimated
with a “local” fit). Principal components analysis (PCA) was performed using
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normalized and transformed counts (variance stabilizing transformation; com-
puted with DESeq2) and the R “prcomp” package. The PCA was performed using
only genes that showed significant variation between the experimental groups (i.e.,
all possible combinations of cell type and condition; DESeq2 LRT test; BH adjusted
p < 0.1).
MicroCT analysis. Hind and front paws of indicated mice were removed and fixed
in 4% formalin. Paws were scanned using a SKYSCAN 1174 Compact Micro-CT
machine (Skyscan, Bruker, Belgium), 50 kV, 800 μA, 8.3 μm isometric voxel reso-
lution, 0.7° rotation step with 0.5 mm Al filter and exposure set to 2000 ms and at
12.57 μm image pixel size. Images were analyzed using Skyscan CT Analyzer
software version 1.13.2.1.
BMMC culture. Total BM cells were isolated by flushing the BM from femur and
tibia of healthy SKG mice using RPMI 1640 supplemented with 10% FCS. A single
cell suspension was obtained and passed through a 70 μm strainer before resus-
pending in complete growth medium (RPMI 1640 supplemented with 10% FCS,
1 mM sodium pyruvate, 4 mM L-glutamine, 25 mM HEPES, 50 µM 2-ME, 10 ng/ml
murine IL-3, nonessential amino acids and 10,000 U/ml penicillin/streptomycin)
and cells were seeded into tissue culture treated T75 flasks (Corning). Two days
after seeding, non-adherent cells were harvested and transferred into fresh medium
in a new tissue culture flask; this was repeated twice weekly. Cell density was
adjusted to a concentration of 1 × 106 cells/ml after the first 2 weeks. Cells were
cultured for a total of 5–6 weeks to obtain a pure population of MC. Cell purity of
~95% was obtained as assessed by co-expression of the markers c-Kit and FcεRI by
flow cytometry.
BMMC activation assays. For cytokine production assays, BMMC were stimu-
lated with vehicle, LPS (100 ng/ml; Sigma-Aldrich) or recombinant murine IL-33
(50 ng/ml; BioLegend) for 16 h, with or without cromolyn sodium (5 mM).
Supernatant was harvested and indicated proteins were quantified by ELISA
according to manufacturers’ instructions. In some cases, brefeldin A (5 µg/ml) was
added for a further 6 h before cells were stained for cytokine production and
assessed by flow cytometry, as described above. β-hexosaminidase release was
measured as described previously70. Briefly, 5 × 104 cells were re-suspended per
well in a 96-well plate in HEPES buffer and rested for 10 min at 37 C before adding
stimulants (IL-33 (50 ng/ml) or PMA (5 ng/ml) and ionomycin (500 ng/ml)) for 30
mins. After this, the plate was centrifuged at 300 g for 5 mins and 50 µl of super-
natant was transferred to a plate containing 100 µl p-nitrophenyl N-acetyl-β-D-
glucosamide (PNAG, Sigma) solution (3.5 mg/ml) per well. In the original plate,
150 µl of 0.1% Triton X-100 solution (Sigma) was added to each well and mixed 5
times before incubating for 10 min at 37 °C. After this, 50 µl of the lysed cell
solution was transferred to a different PNAG plate. Both PNAG plates were
incubated at 37 °C for 90 min before adding 100 µl glycine solution (Sigma). Light
emission was measured with a plate reader at 405 nm, subtracting emission at 620
nm. Release was expressed as a percentage of the total β-hexosaminidase present in
each sample after lysis. All activation assays were completed in triplicate.
Liquid culture of BM HSPCs. Cells (LT-HSCs, ST-HSCs, MPPs, and GMPs) were
sorted for culture from suspensions of cells derived from BM using the gating
strategies outlined above, in “RNA sequencing”. Cells were cultured in 96-well
tissue culture plates, with 500 HSC and 1000 MPP or GMP added to each well in
200 µl of IMDM medium containing L-glutamine and HEPES and supplemented
with 5% FCS, 2-mercaptoethanol (100 µM), penicillin/streptomycin (10,000 U/ml),
nonessential amino acids (1×), sodium pyruvate (1 mM), murine stem cell factor
(20 ng/ml), murine IL-6 (10 ng/ml), murine IL-11 (10 ng/ml), murine IL-3 (10 ng/
ml), murine thrombopoietin (10 ng/ml), and human erythropoietin (10 ng/ml). All
cultures were performed in triplicate, with some also containing recombinant
murine GM-CSF (20 ng/ml). Cells were cultured for 4 days (GMP) or 6 days (LT-
HSCs, ST-HSCs, and MPPs), with 60 µl of medium removed and replaced with
fresh medium every 2 days. After 4–6 days, cells were prepared for flow cytometry
as described above. The myeloid output of stem cells or progenitors was assessed by
expressing the number of CD11bhi cells as a percentage of the live cells harvested at
the end of the culture. Cells were quantified using a hemocytometer. Of note, the
majority of CD11bhi cells were also CD16/32+.
Myeloid output assays from GMPs sorted from the joints. GMPs were sorted
from digested paws by FACS, as described above, and compared to GMPs sorted
from flushed BM. Articular lineage−c-Kit− cells and MEP from BM were also
obtained as controls. The digested tissue of 12 paws from mice injected with
curdlan 4 weeks previously were pooled to obtain a suitable number of cells, and
the BM derived from 4 femurs and 4 tibiae from the same mice were also pooled
for isolation of BM GMP. These cells were cultured in 96 well tissue culture plates
in IMDM medium containing L-glutamine and 25 mM HEPES and supplemented
with 5% fetal bovine serum, MEM nonessential amino acids, penicillin/strepto-
mycin (10,000 U/ml), sodium pyruvate (1 mM), β-mercaptoethanol (50 µM),
recombinant murine GM-CSF (10 ng/ml), recombinant murine IL-9 (50 ng/ml),
recombinant murine IL-3 (20 ng/ml), and recombinant murine stem cell factor
(20 ng/ml). Cell suspensions were all in a total volume of 200 µl, with 1000 cells
added to each well at the beginning of the culture. All cultures were performed in
triplicate. Suspensions were maintained at 37 °C in a 5% CO2 atmosphere, and
60 µl of the medium was removed and replaced with fresh medium every 2 days.
After 4 days, cells were quantified using a hemocytometer. The culture plates were
also centrifuged and resuspended in fixable viability dye for 15 min at 4 °C. The
cells were then washed by adding 100 µl PBS with 0.1% BSA and prepared for
myeloid cell output analysis by flow cytometry, as described above.
GMP transfer experiments. Total BM cells were isolated from femurs and tibiae
of CD45.1+ BALB/c mice (CByJ.SJL(B6)-Ptprca, the Jackson Laboratory) and GMP
were isolated using FACS, as described above. In total, 5 × 104 GMP were trans-
ferred intravenously to congenic CD45.2+ SKG mice 2 weeks after IP injection of
curdlan to trigger inflammation in the joints. CD45.1+ cell infiltration to the
inflamed joints and spleens and differentiation into neutrophils were investigated
using flow cytometry.
CFU assays. CFU-GM derived from FACS-sorted cells were assessed by mixing
1000 sorted GMP from paw or BM in a volume of 100 µl IMDM (with L-glutamine
and 25 mM HEPES) with 1 ml of methylcellulose medium (MethoCult M3434
containing murine stem cell factor, IL-3, IL-6, and EPO). The suspension was
mixed by pipetting and vortexing and applied to 3 cm petri dishes. These dishes
were incubated at 37 °C and 5% CO2. Images of the colonies were acquired after
6 days by bright field microscopy using an Olympus BX51 microscope. Colony
formation assays were performed in duplicate.
For CFU-GM quantification from organ single cell suspensions, BM cells (5 ×
104 cells), splenocytes (1 × 105 cells) or cells isolated by enzymatic digestion of the
soft tissue of the paw joint (3 × 105 cells) were suspended in methylcellulose
medium (Stem Cell Technologies; M3434) to quantify clonogenic myeloid colony
forming units. Morphologic analysis of colony formation was performed after
10–12 days of incubation.
Ex vivo organ explant experiments. Three sections of SI (duodenum, jejunum,
and ileum) (0.25 cm2) and one forepaw were removed and incubated in RPMI
1640 supplemented with 10% FCS and 10,000 U/ml penicillin/streptomycin at
37 °C and 5% CO2 for 16 h. The forepaw was cut into three pieces before incu-
bation. Supernatant was harvested and indicated proteins were quantified by ELISA
according to manufacturers’ instructions. Intestinal cytokine concentrations were
normalized to explant weight. Articular concentrations were expressed as total
cytokine levels released per paw.
Statistical analysis. Statistical analysis was performed with Prism 7.0 (GraphPad
Software). Unless stated otherwise, the nonparametric Mann–Whitney test was
used for all statistical comparisons. Differences were considered statistically sig-
nificant when p < 0.05.
Reporting summary. Further information on research design is available in
the Nature Research Reporting Summary linked to this article.
Data availability
All data associated with this study are available in the main text or the Supplementary
materials. The source data underlying Figs. 1c–g, 3a–i, 4a, c, d, f, g, 5b–e, 6a–f, 7a, b, d–l,
and Supplementary Figs. 1a, b, c, e, f, 2c–g, 3a, c, d, 5a, d–f, 6a–h are provided as a Source
Data file. The RNA-sequencing data have been deposited in GEO (GSE126218).
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